BioSpectrum IndiaVol 24 · Issue 11November 202652 pages
Cover Story · by Ankit Kankar

INDIA 2030

Who Supplies the Next 10 Million?

Mass insulin, premium insulin, diabetes technology and the drugs that delay insulin: four territories, four different contests.

Novo Nordisk is stepping back from human insulin pens, once-weekly insulin has arrived and generic semaglutide launched the day the patent expired. Six million Indians are on insulin today. This cover story maps who is positioned to reach the next ten million, and where every company is likely to sit in 2030.

Click to open

All 52 pages

Tap any page to open it in the print edition

In this issue

Contents

Every story in full text, ready to read on any screen. Filter by desk, search the whole issue, or switch to the printed index.

The print edition

The full November issue exactly as printed, all 52 pages, with every page indexed. Click a page edge or use your arrow keys to turn, zoom in to read the fine print, and share any page with its own link.

CoverCover
1 / 52

Tip: use ← → keys, swipe on touch screens, or double-click a page to zoom.

Voices

Who said what

The leaders, scientists and analysts quoted in this issue. Each quote links back to its story.

Data room

The numbers in this issue

The cover story’s charts and the Trends data, rebuilt so you can hover, filter and compare them.

Cover Story · p.19 · The 2030 market map

Four territories, four different contests

Where the next 10 million Indian patients will be won, and what will decide each contest. Select a territory to highlight who plays there in the table below.

Contenders drawn from announced launches, filings and company disclosures to September 2026. Inclusion does not imply market share. Analysis: BioSpectrum India.
Cover Story · p.19

Who plays where today

Few companies are positioned in more than two of the four territories. Click a column to highlight the companies in it.

Marketed product in IndiaPipeline, supply or partner role
Based on launches, regulatory filings and company disclosures to September 2026. Biocon Biologics supplies insulin to Eris for India and to public programmes abroad; Abbott has marketed Novo Nordisk human insulin in India.
Cover Story · p.15

A market that is still in the waiting room

Roughly one in seventeen Indians with diabetes is on insulin. Figures in millions of people.

Sources: ICMR-INDIAB figures cited by Novo Nordisk; Vikrant Shrotriya, Novo Nordisk India, reported by Reuters, 9 July 2026.
Cover Story · p.16

Filling the gap Novo Nordisk left

Eris Lifesciences’ reported share of India’s human insulin segments during FY26.

Source: Eris Lifesciences Q4 FY26 earnings call, May 2026. Company-reported market shares.
Cover Story · p.18

The semaglutide price floor fell on Day 1

Reported monthly therapy cost at launch after the Indian patent expired on 20 March 2026, rupees.

“From” marks the lowest published starting price; higher doses cost more. Sources: company launch statements; Pearce IP; Multibagg; Eris Lifesciences.
Cover Story · p.18

Knowing your glucose costs more than treating it

Approximate cost per day at Indian list and retail prices, rupees. Hover a bar for the basis.

Per-day figures derived from published prices. Not a clinical comparison. Dexcom G7, at about ₹1,200 a day, sits off this scale.
Trends · p.23

What the NPPA order on 137 cancer medicines requires

Key compliance requirements for pharmaceutical companies under the 30 per cent trade-margin cap, effective 9 November 2026.

RequirementDirection under the NPPA order
Source: NPPA order, as reported by BioSpectrum India.
Trends in numbers · pp.24 and 34

Two markets on the move

India’s anti-neoplastics market (Pharmarack PharmaTrac, September 2026) and India’s laboratory centrifuge market (MarketsandMarkets).

Figures as reported in the November 2026 Trends section.